Stockscreener 앱 받기
23.01
3.32%
-0.79
시간 외 거래:
23.02
0.010
+0.04%
전일 마감가:
$23.80
열려 있는:
$23.73
하루 거래량:
86,761
Relative Volume:
0.43
시가총액:
$824.32M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.22%
1개월 성능:
-11.09%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$22.99
$24.00
1주일 범위
$22.21
$24.71
52주 변동 폭
$18.69
$32.75
Ceribell Inc Stock (CBLL) Company Profile
명칭
Ceribell Inc
전화
(800) 436-0826
주소
360 N. PASTORIA AVENUE, SUNNYVALE
CBLL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
23.01 | 824.32M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
127.93 | 221.89B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
102.36 | 150.86B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
391.29 | 149.17B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.82 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
72.45 | 42.73B | 6.60B | 4.16B | 490.10M | 6.93 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-05 | 개시 | BofA Securities | Buy |
| 2024-11-05 | 개시 | Canaccord Genuity | Buy |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 개시 | William Blair | Outperform |
Ceribell Inc 주식(CBLL)의 최신 뉴스
Nexalin Technology (NASDAQ:NXL) vs. CeriBell (NASDAQ:CBLL) Head-To-Head Contrast - Defense World
CeriBell (NASDAQ:CBLL) Trading 9.1% HigherShould You Buy? - MarketBeat
Beta Bionics targets up to $616 mln valuation in US IPO - Reuters
CeriBell (NASDAQ:CBLL) Receives $32.60 Consensus Price Target from Analysts - Defense World
Brokerages Set CeriBell (NASDAQ:CBLL) Price Target at $32.60 - MarketBeat
Ceribell Expands its Executive Management Team by Two - MPO-mag
CeriBell (NASDAQ:CBLL) Hits New 52-Week LowTime to Sell? - MarketBeat
CeriBell (NASDAQ:CBLL) Shares Down 9.2%Should You Sell? - MarketBeat
CeriBell (NASDAQ:CBLL) Trading Down 3.3%What's Next? - MarketBeat
Contrasting CeriBell (NASDAQ:CBLL) & Cutera (NASDAQ:CUTR) - Defense World
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
CeriBell (NASDAQ:CBLL) Receives $32.60 Consensus PT from Analysts - Defense World
Head to Head Contrast: CeriBell (NASDAQ:CBLL) & Vaso (OTCMKTS:VASO) - Defense World
Ceribell Receives Authority to Operate from the U.S. Department of Veterans Affairs - Marketscreener.com
CeriBell (NASDAQ:CBLL) Shares Down 2.6%Here's Why - MarketBeat
CeriBell (NASDAQ:CBLL) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Ceribell CEO to Present at J.P. Morgan Healthcare Conference 2025: Medical Tech Innovation in Focus - StockTitan
CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - The Eastern Progress Online
CeriBell (NASDAQ:CBLL) Price Target Raised to $33.00 at Canaccord Genuity Group - Defense World
CeriBell (NASDAQ:CBLL) Given New $36.00 Price Target at TD Cowen - Defense World
Ceribell shares PT raised by analyst to reflect higher EV/sales momentum - Investing.com UK
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
Top 145+ startups in Smart EEG Devices in Nov, 2024 - Tracxn
CeriBell: Healthcare Technology Stock With A Promising Growth Outlook (NASDAQ:CBLL) - Seeking Alpha
Ceribell appoints Rodenbush as CPO, Price as SVP of Marketing - TipRanks
Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing - The Manila Times
Ceribell Strengthens Leadership Team with Key AI Medical Device Executives | CBLL Stock News - StockTitan
Meet the biophysicist whose seizure-detection company is using AI to get a better read on people's brains - Fast Company
FY2024 EPS Estimates for CeriBell Reduced by William Blair - MarketBeat
William Blair Estimates CeriBell's Q1 Earnings (NASDAQ:CBLL) - MarketBeat
Ceribell revenue increases 48% to USD 17.2M in Q3 2024 - Medical Buyer
Ceribell, Inc. Reports Strong Q3 2024 Growth - Yahoo Finance
Ceribell price target raised to $31 from $30 at Canaccord - TipRanks
CeriBell (NASDAQ:CBLL) Price Target Raised to $31.00 at Canaccord Genuity Group - MarketBeat
CeriBell’s Quiet Period To End on November 20th (NASDAQ:CBLL) - Defense World
CeriBell's (NASDAQ:CBLL) Quiet Period To End on November 20th - MarketBeat
Ceribell Reports Third Quarter 2024 Financial Results - GlobeNewswire
CeriBell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ceribell Secures VA Authorization, Expands AI-Powered EEG Tech to Veterans Hospitals | CBLL Stock News - StockTitan
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Manila Times
Q3 Earnings Estimate for CeriBell Issued By William Blair - Defense World
Brokerages Set CeriBell (NASDAQ:CBLL) PT at $31.00 - Defense World
Ceribell started with bullish ratings by J.P. Morgan, Canaccord - MSN
Ceribell Inc (CBLL) 재무 분석
Ceribell Inc (CBLL)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.47%
자본화:
|
볼륨(24시간):